REFERENCES
1. Hall E, Dekker Nitert M, Volkov P, Malmgren S, Mulder H, et al. The effects of high glucose exposure on global gene expression and DNA methylation in human pancreatic islets. Mol Cell Endocrinol 2018;472:57-67.
2. Bensellam M, Jonas JC, Laybutt DR. Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions. J Endocrinol 2018;236:R109-43.
3. Robertson RP, Harmon JS, Tanaka Y. Glucose toxicity of the β-cell: cellular and molecular mechanisms. In: Diabetes mellitus. A fundamental and clinical text. 2nd ed. In: Le Roith D, Taylor SI, Olefsky JM, editors. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 125-32.
4. Staiger H, Machicao F, Fritsche A, Häring HU. Pathomechanisms of type 2 diabetes genes. Endocr Rev 2009;30:557-85.
5. Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, et al. Chronic activation of liver X receptor induces β-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic β-cells. Diabetes 2007;56:1534-43.
6. Juntilla M, Wofford JA, Birnbaum MJ, Rathmell JC, Koretzky GA. Akt1 and Akt2 are required for alphabetathymocyte survival and differentiation. ProcNatlAcadSci U S A 2007;104:12105-10.
7. Huang JP, Huang SS, Deng JY, Hung LM. Impairment of insulin-stimulated Akt/GLUT4 signaling is associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic rats. J Biomed Sci 2009;16:77.
8. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Na Cell Biol 2004;6:351-7.
9. Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. BiochimBiophysActa 2009;1792:1080-6.
10. Huo M, Zang HL, Zhang DJ, Wang B, Wu J, et al. Role of increased activity of carbohydrate response element binding protein in excessive lipid accumulation in the liver of type 2 diabetic db/db mouse. Beijing Da Xue Xue Bao Yi Xue Bao 2009;41:307-12. (in Chinese)
11. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr Rev 2007;29:351-66.
12. Ametov AS, Demidova TY, Tselikovskaya AL. Obesity and cardiovascular diseases. Therapeutic Archive 2001;73:66-9. (in Russian)
13. Kaneto H, Miyatsuka T, Shiraiwa T, Yamamoto K, Kato K, et al. Crucial role of PDX-1 in pancreas development, beta-cell differentiation, and induction of surrogate beta-cells. Cur Med Chem 2007;14:1745-52.
14. Nishimura W, Bonner-Weir S, Sharma A. Expression of MafA in pancreatic progenitors is detrimental for pancreatic development. Dev Biol 2009;333:108-20.
15. Artner I, Hang Y, Guo M, Gu G, Stein R. MafA is a dedicated activator of the insulin gene in vivo. J. Endocrinol 2008;198:271-9.
17. Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in β-cell adaptation and failure in the etiology of diabetes. Diabetes 2002;51:S405-13.
18. Ashcroft FM, Rohm M, Clark A, Brereton MF. Is type 2 diabetes a glycogen storage disease of pancreatic β cells? Cell Metab 2017;26:17-23.
20. Schatz H. 2008--The year of the big studies about the therapy of type-2-diabetes. ACCORD, ADVANCE, VADT, and the UKPDS 10-year follow-up data. MMW Fortschr Med 2009;151:42-3.
21. Burkhardt BR, Cook JR, Young RA, Wolf BA. PDX-1 interaction and regulation of the Pancreatic Derived Factor (PANDER, FAM3B) promoter. Biochim Biophys Acta 2008;1779:645-51.
22. Stanojevic V, Habener JF, Thomas MK. Pancreas duodenum homeobox-1 transcriptional activation requires interactions with p300. Endocrinology 2004;145:2918-28.
23. Gao Y, Miyazaki J, Hart GW. The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in min6 ß-cells. Arch Biochem Biophys 2003;415:155-63.
24. Kishi A, Nakamura T, Nishio Y, Maegawa H, Kashiwagi A. Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am J Physiol Endocrinol Metab 2003;284:E830-40.
25. da Silva Xavier G, Varadi A, Ainscow EK, Rutter GA. Regulation of gene expression by glucose in pancreatic ß-cells (MIN6) via insulin secretion and activation of phosphatidylinositol 3’-kinase. J Biol Chem 2000;275:36269-77.
26. Khoo S, Griffen SC, Xia Y, Baer RJ, German MS, et al. Regulation of insulin gene transcription by ERK1 and ERK2 in pancreatic ß cells. J Bio Chem 2003;278:32969-77.
27. Zangen DH, Bonner-Weir S, Lee CH, Latimer JB, Miller CP, et al. Reduced insulin, GLUT2, and IDX-1 in ß-cells after partial pancreatectomy. Diabetes 1997;46:258-64.
28. Leibowitz G, Ferber S, Apelqvist A, Edlund H, Gross DJ, et al. IPF1/PDX1 deficiency and ß-cell dysfunction in Psammomysobesus, an animal with type 2 diabetes. Diabetes 2001;50:1799-806.
29. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A 1999;96:10857-62.
30. Tajiri Y, Moller C, Grill V. Long term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits β-cell function. Endocrinology 1997;138:273-80.
31. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004;53:S110-8.
32. Gopaul NK, Anggård EE, Mallet AI, Betteridge DJ, Wolff SP, et al. Plasma 8-epi-PGF2 levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995;368:225-9.
33. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, et al. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 1995;38:201-10.
34. Chaurasia B, Summers SA. Ceramides - lipotoxic inducers of metabolic disorders: (Trends in Endocrinology and Metabolism 26, 538-550; 2015). Trends Endocrinol Metab 2018;29:66-7.
35. Hagman DK, Hays LB, Parazzoli SD, Poitout V. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. J Biol Chem 2005;280:32413-8.
36. Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V. Lipotoxicity of the pancreatic ß-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 2001;50:315-21.
37. Gwiazda KS, Yang T, Lin Y, Johnson JD. Effects of palmitate on ER and cytosolic Ca2+ homeostasis in beta-cells. Am J Physiol Endocrinol Metab 2009;296:E690-701.
38. Widenmaier SB, Ao Z, Kim SJ, Warnock G, McIntosh CH. Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 2009;284:30372-82.
39. Kaneto H, Miyatsuka T, Shiraiwa T, Yamamoto K, Kato K, et al. Crucial role of PDX-1 in pancreas development, beta-cell differentiation, and induction of surrogate beta-cells. Curr Med Chem 2007;14:1745-52.
40. Vallerie SN, Furuhashi M, Fucho R, Hotamisligil GS. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 2008;3:e3151.
41. Kawamori D, Kaneto H, Nakatani Y, Matsuoka TA, Matsuhisa M, et al. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem 2006;281:1091-8.
42. Weber C, Krueger A, Münk A, Bode C, Van Veldhoven PP, et al. Discontinued postnatal thymocyte development in sphingosine 1-phosphate-lyase-deficient mice. J Immunol 2009;183:4292-301.
43. Zhou YP, Grill V. Long-term exposure to fatty acids and ketones inhibits β-cell functions in human pancreatic islets of Langerhans. J ClinEndocrinol. Metab 1995;80:1584-90.
44. Mason TM, Goh T, Tchipashvili V, Sandhu H, Gupta N, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 1999;48:524-30.
45. Paolisso G, Gambardella A, Amato L, Tortoriello R, D’Amore A, et al. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995;38:1295-9.
46. Liu YQ, Tornheim K, Leahy JL. Fatty-acid induced β-cell hypersensitivity to glucose. Increased phosphofructokinase activity and lowered glucose-6-phosphate content. J Clin Invest 1998;101:1870-5.
47. Magnan C, Collins S, Berthault MF, Kassis N, Vincent M, et al. Lipid infusion lowers sympathetic nervous activity and leads to increased β-cell responsiveness to glucose. J Clin Invest 1999;103:413-9.
48. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, β-cell dysfunction, and type 2 diabetes. Cell 2001;105:745-55.
49. Joseph JW, Koshkin V, Zhang CY, Wang J, Lowell BB, et al. Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet. Diabetes 2002;51:3211-9.
50. Lameloise N, Muzzin P, Prentki M, Assimacopoulos-Jeannet F. Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 2001;50:803-9.
51. Medvedev AV, Robidoux J, Bai X, Cao W, Floering LM, et al. Regulation of the uncoupling protein-2 gene in INS-1 β-cells by oleic acid. J BiolChem 2002;277:42639-44.
52. Medvedev AV, Snedden SK, Raimbault S, Ricquier D, Collins S. Transcriptional regulation of the mouse uncoupling protein-2 gene. Double E-box motif is required for peroxisome proliferator-activated receptor- -dependent activation. J BiolChem 2001;276:10817-23.
53. Roche E, Farfari S, Witters LA, Assimacopoulos-Jeannet F, Thumelin S, et al. Long-term exposure of β-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, andlipogenic gene expression. Diabetes 1998;47:1086-94.
54. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004;3:340-51.
55. Wang X, Zhou L, Li G, Luo T, Gu Y, et al. Palmitate activates AMP-activated protein kinase and regulates insulin secretion from β cells. Biochem Biophys Res Commun 2007;352:463-8.
56. Brøns C, Vaag A. Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes. J Physiol 2009;587:3977-8.
